ecancer

Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma

Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany

3 Oct 2013

Androgen blockade and ipilimumab against castration resistant prostate cancer

Dr Karim Fizazi - Institute Gustave Roussy, Paris, France

3 Oct 2013

ecancerNews Highlights from September 2013

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

24 Sep 2013

Developments with PD1 and immunotherapy in melanoma

Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France

19 Jul 2013

Establishing immunotherapy as a standard in cancer treatment

Prof Drew Pardoll – Johns Hopkins University School of Medicine, Baltimore, USA

18 Jul 2013

ECC 2013 Preview: Scientific programme highlights

Prof Vincenzo Valentini and Ian Banks

11 Jul 2013

Treatment of melanoma in Latin America

Dr Alessandro Testori - European Institute of Oncology, Milan, Italy

9 Jul 2013

Vemurafenib and ipilimumab for metastatic melanoma

Dr Caroline Robert - Institute Gustave Roussy, Paris, France

14 Jun 2013

Role of microenvironment and stroma in cancer therapy

Dr Stephen Ansell - Mayo Clinic, Rochester, USA

7 Jun 2013

Science behind phase I clinical trials: targeting tumour cell development pathways

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

6 Jun 2013

ASCO 2013 highlights

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

6 Jun 2013

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

3 Jun 2013

More from ecancer